VBI Vaccines (VBIV) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChart

VBI Vaccines Revenue Highlights


Latest Revenue (Y)

$8.68M

Latest Revenue (Q)

$1.21M

Main Segment (Y)

Product

Main Geography (Y)

China Hong Kong

VBI Vaccines Revenue by Period


VBI Vaccines Revenue by Year

DateRevenueChange
2023-12-31$8.68M702.40%
2022-12-31$1.08M71.47%
2021-12-31$631.00K-40.53%
2020-12-31$1.06M-52.23%
2019-12-31$2.22M-33.80%
2018-12-31$3.35M287.86%
2017-12-31$865.00K57.85%
2016-12-31$548.00K-42.62%
2015-12-31$955.00K100.00%
2014-03-31-100.00%
2013-03-31-100.00%
2012-03-31-100.00%
2011-03-31-100.00%
2010-03-31-100.00%
2009-03-31-100.00%
2008-03-31-100.00%
2007-03-31-100.00%
2006-03-31-100.00%
2005-03-31--100.00%
2004-03-31$79.32-83.94%
2003-03-31$493.94-2.86%
2002-03-31$508.5080614.29%
2001-03-31$0.63-100.00%
2000-03-31$68.84K3.89%
1999-03-31$66.27K-5.93%
1998-03-31$70.45K-2.79%
1997-03-31$72.47K-

VBI Vaccines generated $8.68M in revenue during NA 2023, up 702.40% compared to the previous quarter, and up 258.78% compared to the same period a year ago.

VBI Vaccines Revenue by Quarter

DateRevenueChange
2024-03-31$1.21M42.32%
2023-12-31$853.00K-87.12%
2023-09-30$6.62M820.00%
2023-06-30$720.00K48.45%
2023-03-31$485.00K65.53%
2022-12-31$293.00K-7.57%
2022-09-30$317.00K-8.38%
2022-06-30$346.00K174.60%
2022-03-31$126.00K55.56%
2021-12-31$81.00K-24.30%
2021-09-30$107.00K-24.65%
2021-06-30$142.00K-52.82%
2021-03-31$301.00K83.54%
2020-12-31$164.00K-44.97%
2020-09-30$298.00K61.96%
2020-06-30$184.00K-55.66%
2020-03-31$415.00K-27.70%
2019-12-31$574.00K-11.28%
2019-09-30$647.00K1.09%
2019-06-30$640.00K77.78%
2019-03-31$360.00K-86.59%
2018-12-31$2.68M936.29%
2018-09-30$259.00K10.68%
2018-06-30$234.00K31.46%
2018-03-31$178.00K-11.44%
2017-12-31$201.00K4.15%
2017-09-30$193.00K-43.90%
2017-06-30$344.00K170.87%
2017-03-31$127.00K-7.30%
2016-12-31$137.00K-51.25%
2016-09-30$281.00K242.68%
2016-06-30$82.00K70.83%
2016-03-31$48.00K-580.00%
2015-12-31$-10.00K-109.62%
2015-09-30$104.00K100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30-100.00%
2012-06-30-100.00%
2012-03-31-100.00%
2011-12-31-100.00%
2011-09-30-100.00%
2011-06-30-100.00%
2011-03-31-100.00%
2010-12-31-100.00%
2010-09-30-100.00%
2010-06-30-100.00%
2010-03-31-100.00%
2009-12-31-100.00%
2009-09-30-100.00%
2009-06-30-100.00%
2009-03-31-100.00%
2008-12-31-100.00%
2008-09-30-100.00%
2008-06-30-100.00%
2008-03-31--

VBI Vaccines generated $1.21M in revenue during Q1 2024, up 42.32% compared to the previous quarter, and up 414.33% compared to the same period a year ago.

VBI Vaccines Revenue Breakdown


VBI Vaccines Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Service$3.99M$151.00K$369.00K--
Product$12.51M$931.00K$262.00K--
License$3.60M----
R&D Services Revenue---$476.00K-
Product Revenue---$8.69M$536.00K
R&D Service Revenue----$1.69M

VBI Vaccines's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (62.24%), Service (19.87%), and License (17.89%).

Quarterly Revenue by Product

Product/ServiceMar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Service$3.23M$569.00K$3.40M$12.00K$7.00K$42.00K$59.00K$15.00K$35.00K$81.00K$83.00K$71.00K$134.00K$94.00K$283.00K$166.00K----
Product$5.49M$6.01M$5.31M$708.00K$478.00K$251.00K$258.00K$331.00K$91.00K-$24.00K$71.00K$167.00K$70.00K$15.00K$18.00K----
License$2.50M-$3.60M-----------------
Product Revenues----------------$180.00K$168.00K$104.00K-
R&D Service Revenues----------------$235.00K$479.00K$536.00K-
R&D Service Revenue-----------------$403.00K--
Product Revenue-----------------$171.00K--

VBI Vaccines's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (48.94%), Service (28.80%), and License (22.27%).

VBI Vaccines Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
ISRAEL$167.00K$315.00K$321.00K$284.00K-
UNITED STATES$1.84M$695.00K---
China Hong Kong$5.58M----
Europe$1.08M$6.00K$4.00K$53.00K$131.00K
China / Hong Kong-$66.00K$306.00K$724.00K-
Israel----$455.00K
China/Hong Kong----$1.64M

VBI Vaccines's latest annual revenue breakdown by geography, as of Dec 23: China Hong Kong (64.33%), UNITED STATES (21.25%), Europe (12.50%), and ISRAEL (1.92%).

Quarterly Revenue by Country

CountryMar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
China and Hong Kong$32.00K-------------------
UNITED STATES$961.00K$325.00K$690.00K$508.00K$322.00K$251.00K$238.00K$207.00K------------
ISRAEL$20.00K$68.00K$42.00K$57.00K$34.00K$60.00K$126.00K$95.00K$21.00K$44.00K$87.00K$169.00K$86.00K$48.00K$19.00K-----
Europe$201.00K$455.00K$330.00K$144.00K$156.00K-$6.00K-$4.00K--$52.00K$16.00K$46.00K$69.00K-----
China Hong Kong-$12.00K$5.56M$11.00K----------------
China / Hong Kong----$7.00K$8.00K$25.00K$60.00K$55.00K$128.00K$78.00K$250.00K$231.00K-------
CANADA--------------------
CHINA---------------$165.00K----
Israel----------------$132.00K$168.00K$134.00K$54.00K
China/Hong Kong-----------------$390.00K$467.00K$517.00K

VBI Vaccines's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (79.16%), Europe (16.56%), China and Hong Kong (2.64%), and ISRAEL (1.65%).

VBI Vaccines Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
ONTXTraws Pharma$226.00B$56.00K
AUPHAurinia Pharmaceuticals$158.53M$55.03M
ARDXArdelyx$124.46M$98.24M
GRTSGritstone bio$16.34M$49.00K
JAGXJaguar Health$9.76M$2.72M
BBIOBridgeBio Pharma$9.30M$2.17M
VBIVVBI Vaccines$8.68M$1.21M
TNXPTonix Pharmaceuticals$7.77M$2.21M
VXRTVaxart$7.38M$6.40M
OCGNOcugen$6.04M$1.14M
ANIXAnixa Biosciences$210.00K-
ALLOAllogene Therapeutics$95.00K$22.00K
GOVXGeoVax Labs--
ANVSAnnovis Bio--
AKROAkero Therapeutics--

VBIV Revenue FAQ


VBI Vaccines's yearly revenue for 2023 was $8.68M, representing an increase of 702.40% compared to 2022. The company's yearly revenue for 2022 was $1.08M, representing an increase of 71.47% compared to 2021. VBIV's yearly revenue for 2021 was $631K, representing a decrease of -40.53% compared to 2020.

VBI Vaccines's quarterly revenue for Q1 2024 was $1.21M, a 42.32% increase from the previous quarter (Q4 2023), and a 150.31% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $853K, a -87.12% decrease from the previous quarter (Q3 2023), and a 191.13% increase year-over-year (Q4 2022). VBIV's quarterly revenue for Q3 2023 was $6.62M, a 820.00% increase from the previous quarter (Q2 2023), and a 1989.59% increase year-over-year (Q3 2022).

VBI Vaccines's revenue growth rate for the last 3 years (2021-2023) was 1275.91%, and for the last 5 years (2019-2023) was 290.90%.

VBI Vaccines's revenue streams in c 23 are Service, Product, and License. Service generated $3.99M in revenue, accounting 19.87% of the company's total revenue, up 2543.71% year-over-year. Product generated $12.51M in revenue, accounting 62.24% of the company's total revenue, up 1243.39% year-over-year. License generated $3.6M in revenue, accounting 17.89% of the company's total revenue

For the fiscal year ending Dec 23, the largest source of revenue of VBI Vaccines was Product. This segment made a revenue of $12.51M, representing 62.24% of the company's total revenue.